Avelumab and Merkel Cell Carcinoma: Evaluating Causation

Legacy of Health Communication and Causality Assessment

General health and science communication has long emphasized the importance of understanding the balance between therapeutic benefits and potential adverse effects of medical interventions. In the context of oncology, this principle extends to evaluating whether a drug might inadvertently contribute to the very condition it is designed to treat. The legacy of health information dissemination has established a framework for assessing causality in medicine, focusing on epidemiological patterns, temporal relationships, and biological plausibility without delving into specific mechanistic pathways. This foundational approach now informs the examination of Avelumab, a PD-L1 inhibitor used in the treatment of Merkel Cell Carcinoma. As clinical experience with immune checkpoint inhibitors expands, a critical question emerges: does Avelumab exposure itself increase the risk of developing Merkel Cell Carcinoma? This inquiry shifts the focus from general health education to a more specialized occupational exposure concern, particularly for healthcare workers and researchers who handle the drug. The transition requires careful consideration of exposure routes, duration, and potential long-term consequences, while maintaining the rigorous standards of causality assessment established in public health discourse. By applying the same analytical rigor used in general health contexts, we can explore whether occupational exposure to Avelumab presents a distinct risk profile for Merkel Cell Carcinoma, separate from its intended therapeutic use.

Bridge: From General Causality to Specific Drug-Disease Inquiry

Building on the foundational principles of causality assessment, we now turn to the specific question of whether Avelumab can cause Merkel Cell Carcinoma (MCC). This inquiry is particularly relevant given that Avelumab is an approved treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The drug is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune response against cancer cells. Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). The evidence does not support a causal relationship in which Avelumab induces the development of MCC; instead, it is a therapeutic agent for the disease.

Clinical Presentation and Diagnosis of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. The disease is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of biopsy specimens, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and chromogranin A.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune response against cancer cells. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab, like other checkpoint inhibitors, is known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported irAEs include hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other adverse effects may include fatigue, infusion-related reactions, and various organ-specific immune toxicities.

Mechanistic Pathways and Evidence Against Causation

The query asks whether Avelumab causes MCC. The evidence does not support a causal relationship in which Avelumab induces the development of MCC. Instead, Avelumab is a treatment for MCC. The drug is designed to treat metastatic MCC by blocking PD-L1, thereby reactivating the immune system to attack cancer cells. Immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). For patients who are refractory to Avelumab, alternative treatments such as ipilimumab plus nivolumab have shown activity (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). There is no evidence to suggest that Avelumab causes MCC; instead, it is a therapeutic agent for the disease.

Adequacy of Warnings and Risk Communication

The evidence indicates that Avelumab is approved specifically for the treatment of metastatic MCC, and its prescribing information includes warnings about immune-related adverse events. However, the evidence does not provide specific details on the adequacy of warnings regarding Avelumab and MCC causation. Given that Avelumab is a treatment for MCC, warnings would logically focus on its therapeutic use and potential side effects, rather than on causing the disease. The evidence does not suggest that Avelumab induces MCC; rather, it is used to treat it.

Timeline and Causation Considerations for Affected Patients

For patients with MCC who are treated with Avelumab, the primary causation consideration is whether the drug is effective in treating the disease. The evidence shows that Avelumab can produce objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who do not respond or who progress on Avelumab, alternative therapies such as ipilimumab plus nivolumab may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence does not document a timeline in which Avelumab exposure leads to the development of MCC. In clinical trials, Avelumab is administered to patients who already have MCC, and the timeline of interest is the time to response or progression. Immune-related adverse events, such as hypercalcaemia due to sarcoidosis, can occur during treatment and may require management with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). The evidence does not indicate that Avelumab causes MCC as a harm; rather, it is used to treat the disease.

Conclusion

Based on the provided evidence, Avelumab does not cause Merkel cell carcinoma. Instead, it is an approved treatment for metastatic MCC, with demonstrated efficacy in a subset of patients. The drug is associated with immune-related adverse events, but there is no evidence linking Avelumab to the induction of MCC. For patients with MCC, Avelumab represents a therapeutic option, and for those who are refractory, alternative checkpoint inhibitor combinations may be considered.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, the evidence does not support that Avelumab causes Merkel cell carcinoma. Avelumab is an approved treatment for metastatic Merkel cell carcinoma and works by blocking PD-L1 to enhance the immune response against cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the adverse effects of Avelumab?

Avelumab can cause immune-related adverse events such as hypercalcaemia secondary to reactivation of sarcoidosis, fatigue, infusion-related reactions, and various organ-specific immune toxicities (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.